论文部分内容阅读
Roussel公司将修改有关前列腺素-j流产药——米非司酮(Mifepristone, Mifegyne)合用的产品介绍,以告诫在使用流产药时采用前列腺素类似物治疗方案必须慎重考虑。这项改变是在收到了一份关于合用米非司酮为主的流产药与前列腺素能引起心肌梗塞和心律不齐的报告后,由药品审批委员会促请作出的。
Roussel will revise its product portfolio on the prostaglandin-j abortion drug Mifepristone (Mifegyne) to warn of the need for careful consideration of prostaglandin analogue regimens when using abortion. The change was prompted by the Drug Approval Committee following receipt of a report that co-administration of mifepristone-based abortion drugs and prostaglandins could cause myocardial infarction and arrhythmia.